BSA
PCRX icon

Braun Stacey Associates’s Pacira BioSciences PCRX Stock Holding History

Braun Stacey Associates’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-5,530
Closed -$336K – 137
2021
Q2 		$336K Sell
5,530
-102,875
-95% -$6.51M 0.01% 126
2021
Q1 		$7.6M Buy
+108,405
New +$7.74M 0.32% 101

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
SCM
Spyglass Capital Management San Francisco, California $1.41B AUM 7.96% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Braun Stacey Associates's PCRX Position: Q3 2021 in Review

Braun Stacey Associates sold out of Pacira BioSciences (PCRX) in Q3 2021, closing a stake of 5,530 shares — an estimated $336K sold.

Braun Stacey Associates first reported a position in PCRX in Q1 2021 and held it in 2 quarters. The position peaked at $7.6M in Q1 2021. 259 funds tracked by Wall St. Rank hold PCRX as of Q3 2021.

  • Braun Stacey Associates reported no remaining Pacira BioSciences position as of Q3 2021 after selling out during the quarter.
  • Braun Stacey Associates sold 5,530 Pacira BioSciences shares in Q3 2021, an estimated $336K.
  • Braun Stacey Associates first reported a position in Pacira BioSciences in Q1 2021 and held it in 2 quarters.
  • Braun Stacey Associates's Pacira BioSciences position peaked at $7.6M in Q1 2021.
  • 259 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2021.

Based on Braun Stacey Associates's 13F filing for Q3 2021, filed 1 Dec 2021.